Личный кабинет Регистрация
ISSN 2413-0346 (Print)
ISSN 2413-0354 (Online)

Аннотация

В обзоре литературы охарактеризованы результаты применения основных методов, применяемых для изучения лекарственной чувствительности микобактерий комплекса M. avium-intracellulare (МАС). При этом основное внимание обращено на препараты, используемые при исследованиях с помощью количественного микрометода серийных разведений
(Sensititre SLOMYCO).
Ключевые слова: лекарственная чувствительность, МАС, Sensititre



Об авторах



Литвинов Виталий Ильич – научный руководитель ГБУЗ «Московский городской научно-практический центр борьбы
с туберкулезом Департамента здравоохранения города Москвы», доктор медицинских наук, профессор, академик РАН
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (495) 268-04-15
e-mail: mnpcbtlv@yandex.ru

Макарова Марина Витальевна – ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза
и патоморфологии ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор биологических наук
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (916) 688-98-25, факс + 7 (495) 964-86-37
e-mail: makarova75@yandex.ru

Хачатурьянц Елена Николаевна – врач-бактериолог ЦБЛ ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (915) 302-15-43, факс + 7 (495) 964-86-37
e-mail: hen65b@mail.ru

Краснова Мария Александровна – ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза и патоморфологии ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», кандидат медицинских наук
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (495) 603-30-33, факс + 7 (499) 785-20-82
e-mail: rna68@rambler.ru

Гунтупова Лидия Доржиевна – заведующая отделением легочного туберкулеза клинико-диагностического центра
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города
Москвы», кандидат медицинских наук
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (499) 267-57-92
e-mail: guntupov@mail.ru

Список литературы

1. Андреевская С.Н., Ларионова Е.Е., Смирнова Т.Г. и др. Лекарственная чувствительность медленнорастущих нетуберкулезных микобактерий //
Туберкулез и болезни легких. – 2016. – № 4. – С. 43-50.
2. Лабораторные исследования при туберкулезе / под ред. В.И. Литвинова, А.М. Мороза. – М.: МНПЦБТ, 2013. – 343 с.
3. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии. – М.: МНПЦБТ, 2008. – 255 с.
4. Нетуберкулезные микобактерии, микобактериозы / под ред. В.И. Литвинова, Е.М. Богородской, С.Е. Борисова. – М.: МНПЦБТ, 2014. – 254 с.
5. Оттен Т.Ф., Васильев А.В. Микобактериоз. – СПб.: Мед. пресса, 2005. – 224 с.
6. Abuali M.M., Katariwala R., LaBombardi V.J. A comparison of the Sensititre®MYCOTB panel and the agar proportion method for the susceptibility testing
of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31. – N. 5. – P. 835-839.
7. Ahmed I., Jabeen K., Hasan R. Identification of non-tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital: a cross-sectional
study // BMC Infect. Dis. – 2013. – Vol. 13. – Р. 493.
8. Alcaide F., Calatayud L., Santín M., Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four
conventional antimycobacterial drugs against Mycobacterium kansasii // Antimicrob. Agents. Chemother. – 2004. – Vol. 48. – N. 12. – Р. 4562-4565.
9. Alcaide F., Esteban J., González-Martin J., Palacios J. Methods for determining the antimicrobial susceptibility of mycobacteria // Enferm. Infec. Microbiol.
Clin. – 2016. – S0213-005X(16). – Р. 30103-3.
10. Babady N., Hall L., Abbenyi A. et al. Evaluation of Mycobacterium aviumcomplex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and
Just-One strips // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 5. – Р. 1749-1752. 11. Benson C., Williams P., Cohn D. et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex
disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs
for Clinical Research on AIDS 009 Protocol Team // J. Infect. Dis. – 2000. – Vol.181. – N. 4. – Р. 1289-1297.
12. Brown-Elliott B., Griffith D., Wallace R. Diagnosis of nontuberculous mycobacterial infections // J. Clin. Lab. Med. – 2002. – Vol. 22. – Р. 911-925.
13. Brown-Elliott B., Wallace R. Infections caused by nontuberculous mycobacteria // In: Principles and Practice of Infectious Disease / ed. by G. Mandell. –
2005. – Vol. 2. – Р. 2909-2916.
14. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – Р. 545-582.
15. Brown-Elliott B., Iakhiaeva E., Griffith D. et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints
and finding of a 16S rRNA gene mutation in treated isolates // J. Clin. Microbiol. – 2013. – Vol. 51. – N. 10. – Р. 3389-3394.
16. Cavusoglu C., Soyler I., Akinci P. Activities of Linezolid against nontuberculous mycobacteria // New. Microbiol. – 2007. – Vol. 30. – N. 4. – Р. 411-414.
17. CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard – second edition // CLSI document M24-A2.
Wayne, PA: Clinical and Laboratory Standards Institute, 2011. [Электронный документ] URL: http://shop.clsi.org/site/Sample_pdf/M24A2_sample.pdf
(Дата обращения 12.10.2016).
18. Chaisson R., Benson C., Dube M. et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind,
dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team // Ann. Intern. Med. – 1994. – Vol. 121. – N. 12. – Р. 905-911.
19. Craft J., Notario G., Grosset J., Heifets L. Clarithromycin resistance and susceptibility patterns of Mycobacterium aviumstrains isolated during prophylaxis
for disseminated infection in patients with AIDS // Clin. Infect. Dis. – 1998. – Vol. 27. – N. 4. – Р. 807-812.
20. Daley C. Mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – Р. 1-22.
21. Deshpande D., Srivastava S., Meek C. et al. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint
identification for treatment of disseminated Mycobacteriumavium infection // Antimicrob. Agents. Chemother. – 2010. – Vol. 54. – N. 6. – Р. 2534-2539.
22. Deshpande D., Gumbo T. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium // Future Microbiol. – 2011. –
Vol. 6. – N. 4. – Р. 433-439.
23. Duan H., Liang Q., Chu N., Huang H. Macrolide and linezolid susceptibility testing for Mycobacterium intracellulare isolates // Zhonghua J. He He Hu Xi ZaZhi. –
2014. – Vol. 37. – N. 4. – Р. 266-269.
24. Dubé M., Sattler F., Torriani F. et al. The randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy California Collaborative Treatment Group // J. Infect. Dis. – 1997. –
Vol. 176. – N. 5. – Р. 1225-1232.
25. Falkinham J. Current epidemiologic trends of the nontuberculous mycobacteria (NTM) // Curr. Environ. Health. Rep. – 2016. – Vol. 3. – N. 2. – P. 161-167.
26. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria // Chest. – 2008. – Vol. 133. – N. 1. – Р. 243-251.
27. Griffith D., Aksamit T., Brown-Elliott B. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases //
J. Respir. Crit. Care Med. – 2007. – Vol. 175. – N. 4. – Р. 367-416.
28. Hall L., Jude K. P., Clark S.L. et al. Evaluation of the SensititreMycoTB plate for susceptibility testing of the Mycobacterium tuberculosis сomplex against
first- and second-line agents //J. Clin. Microbiol. – 2012. –Vol. 50. – N. 11. – Р. 3732-3734.
29. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs // Antimicrob. Agents.
Chemother. – 1988(а). – Vol. 32. – N. 8. – Р. 1131-1136.
30. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology // Am. Rev. Respir. Dis. – 1988(b). – Vol. 137. – N. 5. – P. 1217-1222.
31. Heifets L. Antimycobacterial drugs // Semin. Respir. Infect. – 1994. – Vol. 9. – N. 2. –Р. 84-103.
32. Heifets L. Clarithromycin against Mycobacterium avium complex infections // Tuber. Lung. Dis. – 1996(а). – Vol. 77. – N. 1. – Р. 19-26.
33. Heifets L. Clinical mycobacteriology. Drug susceptibility testing // Clin. Lab. Med. – 1996(b). – Vol. 16. – N. 3. – Р. 641-656.
34. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates // Antimicrob. Agents. Chemother. – 1996(c). –Vol. 40. – N. 8. – P. 1759-1767.
35. Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria // Semin. In Respir. Crit. Care Med. – 2004. – Vol.25. – N. 3. – Р. 283-295.
36. Heifets L., Iseman M., Lindholm-Levy P. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis // Antimicrob.
Agents. Chemother. – 1986. – Vol. 30. – N. 6. –Р. 927-932.
37. Heifets L., Iseman M., Lindholm-Levy P. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal
synergistic, and bacteriostatic additive or synergistic effects // Am. Rev. Respir. Dis. – 1988. – Vol. 137. – N. 3. – Р. 711-715.
38. Heifets L., Lindholm-Levy P. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium
and M. tuberculosis // Antimicrob. Agents. Chemother. – 1989. – Vol. 33. – N. 8. – Р. 1298-1301.
39. Heifets L., Iseman M. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility // N. Engl. J. Med. – 1990. –
Vol. 323. – N. 6. – Р. 419-420.
40. Heifets L., Lindholm-Levy P., Flory M. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium
and Mycobacterium tuberculosis // Am. Rev. Respir. Dis. – 1991. – Vol. 143. – N. 2. – Р. 268-270.
41. Heifets L., Lindholm-Levy P., Comstock R. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium // Am. Rev.
Respir. Dis. – 1992(а). – Vol. 145. – N. 4. – Pt. 1. – Р. 856-858.42. Heifets L., Lindholm-Levy P., Comstock R. Bacteriostatic and bactericidal activities of gentamycin alone and in combination with clarithromycin against
Mycobacterium avium // Antimicrob. Agents. Chemother. – 1992(b). – Vol. 36. – N. 8. – Р. 1695-1698.
43. Heifets L., Jenkins P. Speciation of micobacteria in clinical laboratories // In: Mycobacteria. Basic aspects / ed. by P. Gangadharam, P. Jenkins. – NY.:
Chapman a Hall (Inf. Thompson Publishing), 1998. – Vol. 1. – Р. 308-350.
44. Horsburgh C., Mason U., Heifets L. et al. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro
susceptibility testing // Am. Rev. Respir. Dis. – 1987. – Vol. 135. – N. 2. – Р. 418-421.
45. Iseman M. Medical management of pulmonary disease caused by M. Avium complex // Clin. Chest. Med. – 2003. – Vol. 23. – Р. 633-641.
46. Kawahara S., Tada A., Nagare H. Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various
mycobacteria // Kekkaku. – 2001. – Vol. 76. – N. 4. – Р. 357-362.
47. Klemens S., Grossi M., Cynamon M. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex // Antimicrob. Agents.
Chemother. – 1994. – Vol. 38. – N. 2. – Р. 234-237.
48. Klopman G., Wang S., Jacobs M. et al. Anti-Mycobacterium avium activity of quinolones: in vitro activities // Antimicrob. Agents. Chemother. – 1993(а). –
Vol. 37. – N. 9. – Р. 1799-1806.
49. Klopman G., Wang S., Jacobs M., Ellner J. Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies // Antimicrob.Agents.
Chemother. – 1993(b). – Vol. 37. – N. 9. – Р. 1807-1815.
50. Klopman G., Li J., Wang S. et al. In vitroanti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerations //
Antimicrob. Agents. Chemother. – 1994. – Vol. 38. – N. 8. – Р. 1794-1802.
51. Lee J., Armstrong D., Ssengooba W. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second – line drugs //
Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – Р. 11-18.
52. Li G., Lian L., Wan L. et al. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay // PLoS. One. –
2013. – Vol. 8. – N. 12. – e84065.
53. Molicotti P., Ortu S., Bua A. et al. In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria // New Microbiol. –
2006. – Vol. 29. – N. 4. – Р. 275-280.
54. Moon S., Park H., Kim S. et al., Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium
avium complex lung disease // Antimicrob. Agents. Chemother. – 2016. – pii: AAC. 01240-16.
55. Mor N., Vanderkolk J., Mezo N., Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication
of Mycobacterium avium // Antimicrob. Agents. Chemother. – 1994. – Vol. 38. – N. 12. – Р. 2738-2742.
56. Nie W., Duan H., Huang H. et al. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis mycobacteria isolates //
Biomed. Res. Int. – 2015. – Р. 506-598.
57. Park J. Recent advances in tuberculosis and nontuberculous mycobacteria lung disease // Tuberc. Respir. Dis. (Seoul). – 2013. – Vol. 74. – N. 6. – Р. 251-255.
58. Rastogi N., Bauriaud R., Bourgoin A. et al. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial
agents against Mycobacterium avium complex // Antimicrob. Agents. Chemother. – 1995. – Vol. 39. – N. 3. – Р. 638-644.
59. Raszka W., Skillman L., McEvoy P. In vitro susceptibility of clinical isolates of Mycobacterium avium and M. intracellulare to folate antagonists //
Diagn. Microbiol. Infect. Dis. – 1994. – Vol. 18. – N. 3. – Р. 201-204.
60. Renvoisé A., Bernard C., Veziris N. et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacteriumintracellulare // J. Clin. Microbiol. – 2014. – Vol. 52. – N. 12. –Р. 4439-4440.
61. Ryu Y., Koh W., Daley C. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians’ perspectives // Tuberc. Respir. Dis. (Seoul). – 2016. –
Vol. 79. – N. 2. – P. 74-84.
62. Shafran S. Clarithromycin prophylaxis for disseminated Mycobacterium avium complex infection – efficacy and acquired resistance // Clin. Infect. Dis. –
1998(a). – Vol. 27. – N. 4. – Р. 813-815.
63. Shafran S. Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals //
Int. J. Infect. Dis. – 1998(b). – Vol. 3. – N. 1. – Р. 39-47.
64. Siddiqi S., Heifets L., Cynamon M. et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates // J. Clin. Microbiol. –
1993. – Vol. 31. – N. 9. – Р. 2332-2338.
65. Slany M., Ulmann V., Slana I. Avian mycobacteriosis: still existing threat to humans // Eur. J. Clin. Microbiol. Infect. Dis. – 2014. – Vol. 33. – N. 3. – P. 347-358.
66. Stout J., Koh W., Yew W. Update on pulmonary disease due to non-tuberculous mycobacteria // Int. J. Infect. Dis. – 2016. –Vol. 45. – P. 123-134.
67. Tomioka H., Sato K., Saito H. In vitro susceptibilities of Mycobacteriumavium and Mycobacterium intracellulare to various drugs // Kekkaku. – 1991. –
Vol. 66. – N. 7. – Р. 489-492.
68. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin. Microbiol. Infect. – 2009. – Vol. 15. – N. 10. – Р. 906-910.
69. Tsukamura M., Ichiyama S. Correlation of minimal inhibitory concentration values of antituberculosis agents against Mycobacterium avium complex
strains with incubation period // Kekkaku. – 1988(а). – Vol. 63. – N. 2. – Р. 107-110.
70. Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium aviumcomplex //
Am. Rev. Respir. Dis. – 1988(b). – Vol. 137. – N. 1. – Р. 144-14871. van Ingen J., Egelund E., Levin A. et al.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment //
Am. J. Respir. Crit. Care Med. – 2012(а). – Vol. 186. – N. 6. – Р. 559-565.
72. van Ingen J., Totten S., Helstrom N. et al. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease //
Antimicrob. Agents. Chemother. – 2012(b). – Vol. 56. – N. 12. – Р. 6324-6327.
73. van Ingen J. Diagnosis of nontuberculous mycobacterial infections // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – Р. 103-109.
74. Venugopal D., Kumar S., Isa M., Bose M. Drug resistance profile of human Mycobacterium avium complex strains from India // Indian. J. Med. Microbiol. –
2007. – Vol. 25. – N. 2. – Р. 115-120.
75. Wallace R., Brown-Elliott B., Crist C. et al. Comparison of the in vitro activity of the glycylcyclinetigecycline (formerly GAR-936) with those of tetracycline,
minocycline, and doxycycline against isolates of nontuberculous mycobacteria // Antimicrob. Agents. Chemother. – 2002. – Vol. 46. – N. 10. – Р. 3164-3167.
76. Ward T., Rimland D., Kauffman C. et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy
for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium //
Clin. Infect. Dis. – 1998. – Vol. 27. – N. 5. – Р. 1278-1285.
77. Woods G. Susceptibility testing for mycobacteria // Clin. Infect. Dis. – 2000. – Vol. 31. – N. 5. – Р. 1209-1215.
78. Woods G., Williams-Bouyer N., Wallace R. et al. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex // J. Clin. Microbiol. – 2003. – Vol. 41. – N. 2. – Р. 627-631.
79. Xu H., Jiang R., Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis // Eur. J. Clin. Microbiol. Infect. Dis. –
2014. – Vol. 33. – N. 3. – P. 347-358.
80. Zhang Z, Pang Y, Wang Y et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung
diseases in China // Int. J. Antimicrob. Agents. – 2015. – Vol. 45. – N. 5. – P. 491-495.